MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
1.730
+0.160 (10.19%)
At close: Oct 29, 2024, 4:00 PM
1.710
-0.020 (-1.16%)
Pre-market: Oct 30, 2024, 4:40 AM EDT
MIRA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for MIRA stock have an average target of 14, with a low estimate of 11 and a high estimate of 17. The average target predicts an increase of 709.25% from the current stock price of 1.73.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2024.
Analyst Ratings
The average analyst rating for MIRA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 |
---|---|---|---|
Strong Buy | 1 | 2 | 2 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +882.66% | Sep 30, 2024 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +535.84% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.55
from -0.65
EPS Next Year
-0.58
from -0.55
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | n/a | n/a | 579.6M |
Avg | n/a | n/a | 281.5M |
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -0.53 | -0.46 | -0.56 |
Avg | -0.55 | -0.58 | -0.54 |
Low | -0.59 | -0.71 | -0.52 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.